Oral MS Therapies Move Closer, But Still Far From Approval And Adoption
Executive Summary
The arrival of an oral therapy for multiple sclerosis moved closer on Sept. 30, but it will still be an uphill climb: first to get past regulators, and then to gain acceptance from a skeptical field of prescribers
You may also be interested in...
Merck KGaA And Novartis Back In Horse Race For First Oral MS Drug To Market
FDA granted the reworked cladribine NDA submitted in June by U.S. affiliate EMD Serono a six-month priority review, with approval possible in the fourth quarter, while action is anticipated on Gilenia in September.
Merck KGaA And Novartis Back In Horse Race For First Oral MS Drug To Market
FDA granted the reworked cladribine NDA submitted in June by U.S. affiliate EMD Serono a six-month priority review, with approval possible in the fourth quarter, while action is anticipated on Gilenia in September.
Follow-on Biologic's Day Will Come - Post 2015, Teva Says
The generic giant acknowledges biogenerics as a major growth driver, but probably not before 2015.